hrcak mascot   Srce   HID

Sažetak sa skupa

Solitary brain metastasis of HER-2 positive breast cancer in a young premenopausal woman

Anamaria Dukić ; School of Medicine, University of Zagreb
Katarina Čular ; School of Medicine, University of Zagreb
Natalija Dedić-Plaveti ; University Hospital Centre Zagreb, Department of Oncology

Puni tekst: engleski, pdf (67 KB) str. 0-0 preuzimanja: 14* citiraj
APA 6th Edition
Dukić, A., Čular, K. i Dedić-Plaveti, N. (2019). Solitary brain metastasis of HER-2 positive breast cancer in a young premenopausal woman. Liječnički vjesnik, 141 (suppl.1), 0-0. Preuzeto s https://hrcak.srce.hr/225192
MLA 8th Edition
Dukić, Anamaria, et al. "Solitary brain metastasis of HER-2 positive breast cancer in a young premenopausal woman." Liječnički vjesnik, vol. 141, br. suppl.1, 2019, str. 0-0. https://hrcak.srce.hr/225192. Citirano 16.12.2019.
Chicago 17th Edition
Dukić, Anamaria, Katarina Čular i Natalija Dedić-Plaveti. "Solitary brain metastasis of HER-2 positive breast cancer in a young premenopausal woman." Liječnički vjesnik 141, br. suppl.1 (2019): 0-0. https://hrcak.srce.hr/225192
Harvard
Dukić, A., Čular, K., i Dedić-Plaveti, N. (2019). 'Solitary brain metastasis of HER-2 positive breast cancer in a young premenopausal woman', Liječnički vjesnik, 141(suppl.1), str. 0-0. Preuzeto s: https://hrcak.srce.hr/225192 (Datum pristupa: 16.12.2019.)
Vancouver
Dukić A, Čular K, Dedić-Plaveti N. Solitary brain metastasis of HER-2 positive breast cancer in a young premenopausal woman. Liječnički vjesnik [Internet]. 2019 [pristupljeno 16.12.2019.];141(suppl.1):0-0. Dostupno na: https://hrcak.srce.hr/225192
IEEE
A. Dukić, K. Čular i N. Dedić-Plaveti, "Solitary brain metastasis of HER-2 positive breast cancer in a young premenopausal woman", Liječnički vjesnik, vol.141, br. suppl.1, str. 0-0, 2019. [Online]. Dostupno na: https://hrcak.srce.hr/225192. [Citirano: 16.12.2019.]

Sažetak
Breast cancer is the most common invasive cancer in women worldwide. It is the second leading cause of cancer death in women. Most frequently it metastasizes to the liver, lungs, bones, brain and lymph nodes. The treatment depends on the tumor’s subtype, including hormone receptor status, such as estrogen and progesterone and HER2 status. Furthermore, it depends on the stage of the tumor, genomic markers, patient’s age, general health, and menopausal status. The patient is a 31-year old female who was diagnosed with invasive breast cancer and underwent surgery at the end of 2015. PHD showed an invasive cancer with estrogen and progesterone receptor positivity of 70%, Her2+ luminal B and T2N1M0. She was treated with adjuvant chemotherapy with doxorubicin and cyclophosphamide, along with pegfilgrastim, paclitaxel and transtuzumab. Afterwards, she had radiotherapy, 50Gy in 25 fractions. Next, she got adjuvant hormone therapy with tamoxifen and goserelin, later replaced by exemestane. In 2017, she had endometrial hyperplasia and underwent curettage. Because of metrorrhagia she had hysteroscopy with polypectomy and myomectomy. At the beginning of 2019, she had severe headaches so MSCT was done. She was diagnosed with metastatic brain tumor in the right parietal lobe, Her2+ and ER and PR negative. The patient is now recovering from brain surgery and stereotactic radiosurgery is being considered. Solitary brain metastasis without visceral metastases requires a specialized management approach. Systemic therapy is continued, and local treatment is added, resection followed by radiotherapy.

Ključne riječi
Advanced breast cancer, chemotherapy, radiotherapy, hormone therapy, brain metastasis

Hrčak ID: 225192

URI
https://hrcak.srce.hr/225192

Posjeta: 37 *